OMER(OMER)
OMER
ANALYST COVERAGE19 analysts
BUY
▲ +226.5%upside to target
PRICE
Prev Close
13.28
Open
12.86
Day Range11.80 – 13.00
11.80
13.00
52W Range2.95 – 17.65
2.95
17.65
63% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
10.8x
Value territory
EPS (TTM)
—
Div Yield
No dividend
Beta
1.87
High vol
TECHNICAL
RSI (14)
62
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 18
DEx-Dividend
In 89 days
Aug 14
PDividend Pay
In 92 days
Aug 17
Key MetricsTTM
Market Cap$886.60M
Revenue TTM$9.89M
Net Income TTM$86.17M
Free Cash Flow-$94.78M
Gross Margin-12.4%
Operating Margin-1063.9%
Net Margin871.0%
Return on Equity-54.4%
Return on Assets30.1%
Debt / Equity-0.19
Current Ratio3.03
EPS TTM$1.20
OMER News
About
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Gregory Demopulos
Website
Catherine A. MelfiChief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems
George A. GaitanarisChief Scientific Officer & Vice President of Science
Gregory A. DemopulosCo-Founder, Chairman, Chief Executive Officer & President
David J. BorgesVice President of Finance, Chief Accounting Officer & Treasurer
David W. GhesquiereVice President & Chief Business Development Officer
Peter CancelmoVice President, General Counsel & Corporate Secretary
Peter W. WilliamsVice President of Human Resources
Nadia DacVice President & Chief Commercial Officer
Andreas GrauerVice President & Chief Medical Officer
Pamela Pierce PalmerCo-Founder